Stephen Charles Emery

USPTO Granted Patents = 8 (Patent Applications = 6)

CIPO Patents = 1 (Patent Applications = 2)

EPO Patents = 1 (Patent Applications = 5)

Average Co-Inventor Count = 2.7

ph-index = 3

Forward Citations = 65(Granted Patents)

Location History:

Macclesfield, GB (2001 - 2011)
Winterley, GB (2011 - 2018)

Company Filing History:

Astra Zeneca U.k. Limited

Years Active: 2001-2018

Loading Chart...

8 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10066011 - Antibodies directed to angiopoietin-2 and uses thereof (2018-09-04),

2. 8834880 - Antibodies directed to angiopoietin-2 and uses thereof (2014-09-16),

3. 8026344 - Targeted binding agents directed to uPAR and uses thereof (2011-09-27),

4. 7973140 - Antibodies directed to angiopoietin-2 and uses thereof (2011-07-05),

5. 6903203 - Monoclonal antibody to CEA, conjugates comprising said antibody and their therapeutic use (2005-06-07),

6. 6838446 - Vector for expression of GPI-enzyme hybrid (2005-01-04),

7. 6339070 - Gene construct encoding a heterologous prodrug-activating enzyme and a cell targeting moiety (2002-01-15),

8. 6277599 - Anti-CEA antibody designated 806.077, hybridoma and method of manufacture (2001-08-21),

Title: The Innovations of Stephen Charles Emery

Introduction

Stephen Charles Emery is a notable inventor based in Winterley, GB. He has made significant contributions to the field of biotechnology, particularly in the development of antibodies. With a total of 8 patents to his name, Emery's work has had a profound impact on medical research and therapeutic applications.

Latest Patents

One of Emery's latest patents focuses on antibodies directed to angiopoietin-2, a crucial protein involved in blood vessel formation. This patent describes fully human monoclonal antibodies that target the antigen Ang-2. The patent also includes nucleotide sequences encoding heavy and light chain immunoglobulin molecules, which are essential for the development of these antibodies. Additionally, it covers hybridomas and other cell lines that express these immunoglobulin molecules and monoclonal antibodies.

Career Highlights

Throughout his career, Stephen Emery has worked with prominent companies in the biotechnology sector. Notably, he has been associated with Medimmune Limited and Zeneca Limited, where he contributed to various innovative projects. His expertise in antibody development has positioned him as a key figure in the industry.

Collaborations

Emery has collaborated with several professionals in his field, including Qing Zhou and David Charles Blakey. These collaborations have further enhanced his research and development efforts, leading to advancements in therapeutic antibodies.

Conclusion

Stephen Charles Emery's contributions to biotechnology and antibody research are noteworthy. His innovative patents and collaborations have significantly advanced the field, making him a respected inventor in the industry.

This text is generated by artificial intelligence and may not be accurate.